Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$70.57 USD
+0.20 (0.28%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $70.64 +0.07 (0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LGND 70.57 +0.20(0.28%)
Will LGND be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LGND based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LGND
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
LGND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
Other News for LGND
Tourlite Capital Q1 2024 Investor Letter
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
Ligand Pharma (LGND) Gets a Buy from Barclays
Jazz Pharmaceuticals: Cheap But Complicated
J&J sets guidance below consensus as MedTech underperforms